Koru can be best described as a pharmaceutical center of research in the age of agile, a fast-growing pharmaceutical research and development group, bringing together an expansive pool of high-value experts under one umbrella and offering complex, technologically advanced platforms targeting serious human disease Koru’s business model fundamentally depends on product innovation to create value by delivering greater customer benefits. Further, sustainable growth and values creation depend on steady R&D productivity with a positive ROI in order to drive future revenues that can be reinvested back into R&D Koru has a strong focus on “agility” to speed the development of products that better meet customer needs. The attractiveness of agility stems from its potential to increase time spent on value-added work and ensure decisions take days, not months, to enable faster reallocation of resources and to enhance engagement—all of which ultimately translates into dramatically reduced time to market. Koru established its first center of pharmaceutical research in Auckland, New Zealand in 2017. This laboratory has been very successful in delivering high-value assets to Global partners. Key technology platforms that were added to the facility were OROS, MUPS, SEDDS. Koru is now expanding its research by establishing research facilities in China and EMA region to increase focus on Lyophilisation, long-acting injectables and further collaborate with industry partners to offer disease management solutions using platform technologies.